Neuroendocrine Cancer treatment response test, PPQ, delivers 96% accuracy

神经内分泌癌症治疗反应测试，PPQ，提供96%的准确性

BRANFORD, Conn. — Sept. XX — The PRRT Predictor Quotient, or PPQ, is the only diagnostic available today to predict patient response to peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors. PRRT is an emerging treatment that delivers targeted doses of radiation to neuroendocrine tumors to slow growth and relieve symptoms..

BRANFORD，Conn.-Sept.XX-PRRT预测商或PPQ是目前唯一可用于预测患者对神经内分泌肿瘤肽受体放射性核素治疗（PRRT）反应的诊断方法。PRRT是一种新兴的治疗方法，可向神经内分泌肿瘤提供靶向剂量的辐射，以减缓生长并缓解症状。。

Wren’s PPQ, a companion test to Wren Laboratories’ NETest®, classifies patients as either a “Responder” who will experience disease stabilization and have a longer time to disease progression (usually greater than 18 months after the end of PRRT treatment), or as a “Non-responder,”  who will have a shorter time until the disease progresses (usually less than 12 months after the start of PRRT).

Wren的PPQ是Wren Laboratories的NETest®的配套测试，将患者分类为“应答者”，他们将经历疾病稳定并具有更长的疾病进展时间（通常在PRRT治疗结束后超过18个月），或作为“无反应者”，直到疾病进展的时间更短（通常在PRRT开始后不到12个月）。

Patients predicted as “Non-responders” may require additional or alternative therapies to stabilize their disease..

被预测为“无反应”的患者可能需要其他疗法或替代疗法来稳定疾病。。

According to recent peer-reviewed research led by Dr. Lisa Bodei at Memorial Sloan Kettering Cancer Center and published in the April 2023 “Journal of Nuclear Medicine,” the PPQ delivers 96% accuracy in determining patient response to PRRT. Moreover, the research also validated the NETest as providing a high accuracy (90%) in monitoring PRRT treatment response..

根据纪念斯隆凯特琳癌症中心的Lisa Bodei博士最近发表的并于2023年4月发表的“核医学杂志”的同行评议研究，PPQ在确定患者对PRRT的反应方面提供了96%的准确性。此外，该研究还验证了NETest在监测PRRT治疗反应方面提供了高精度（90%）。。

“We developed our PRRT predictive quotient, the PPQ, to help identify which NET patients would respond favorably to this particular neuroendocrine cancer treatment. And, equally important, which may not,” said Wren General Manager Dan Buck. “The research done by Dr. Bodei and her colleagues at Memorial Sloan Kettering indicating a 96% level of accuracy in PRRT response prediction should provide patients and physicians alike with a high level of confidence in developing a NET treatment plan.”.

Wren总经理Dan Buck说：“我们开发了PRRT预测商PPQ，以帮助确定哪些NET患者对这种特殊的神经内分泌癌症治疗会有良好的反应，同样重要的是，可能不会。“Bodei博士及其同事在Memorial Sloan Kettering所做的研究表明，PRRT反应预测的准确率为96%，应该为患者和医生提供高度的信心来制定净治疗计划。”。

The Wren Laboratories NETest assay is generally used after diagnosis of a NET, which represents about 2% of all cancer patients. The PPQ, which utilizes a subset of the 51 markers in the NETest, can be subsequently employed when planning therapy for patients diagnosed with those types of neuroendocrine tumors that respond to PRRT:  those having a tendency to express specific receptors that can be targeted with radiolabeled peptides and are radiosensitive. .

Wren Laboratories NETest测定通常在NET诊断后使用，NET占所有癌症患者的约2%。PPQ利用NETest中51个标志物的一个子集，随后可用于计划对诊断为对PRRT有反应的那些类型的神经内分泌肿瘤的患者进行治疗：那些倾向于表达可被放射性标记靶向的特异性受体的患者肽并且是放射敏感的。 .

“The PPQ is an algorithm that integrates radiation-responsive genes with tumor grade. This is more accurate than clinical factors or other biomarkers and is now independently validated,” said Mark Kidd, Ph.D., laboratory and science director at Wren.

Wren实验室和科学主任Mark Kidd博士说：“PPQ是一种将辐射响应基因与肿瘤分级相结合的算法，它比临床因素或其他生物标志物更准确，现在可以独立验证。”。

As PRRT is only available at specialized treatment centers, requiring multiple rounds of costly treatment, using the PPQ can save patients and oncologists time by identifying those patients who would most likely benefit from PRRT.  Additionally, the test can save insurance companies and other payers thousands of dollars in treatment costs by determining the effectiveness before beginning this type of therapy..

由于PRRT仅在专业治疗中心提供，需要多轮昂贵的治疗，因此使用PPQ可以通过识别最有可能从PRRT获益的患者来节省患者和肿瘤学家的时间。此外，通过在开始此类治疗之前确定有效性，该测试可以为保险公司和其他付款人节省数千美元的治疗费用。。

###

###

Wren Laboratories is a molecular diagnostic laboratory in Branford, CT that uses mRNA, artificial intelligence, and a suite of proprietary algorithms to detect cancers and provide diagnostic information to oncologists and patients. Wren is CLIA-certified and CAP-accredited clinical laboratory whose current laboratory developed tests include the NETest and PPQ.

Wren实验室是位于康涅狄格州布兰福德的分子诊断实验室，使用mRNA，人工智能和一套专有算法检测癌症并向肿瘤学家和患者提供诊断信息。Wren是CLIA认证和CAP认证的临床实验室，其当前实验室开发的测试包括NETest和PPQ。

Learn more: wrenlaboratories.com.

了解更多信息：wrenlaboratories.com。